The second analysis, published in 2021, reported the results specifically for 126 enrolled patients (from 2019 to 2020) with NSCLC, mainly previously treated either with platinum-based therapy or with anti-PD1/anti-PD-L1 antibodies [176]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.